Loading
Record, for every patient, the order of treatments and what happened, so that the most common sequences can be compared and the worst ones flagged.
Approved drugs multiply faster than sequencing trials. A national or multi-centre registry capturing line-by-line therapy and outcomes (as the Flatiron and Dutch cancer registries partly do) with a public dashboard of sequence performance would let clinicians see which sequences are common and which look poor, and give trialists the effect sizes needed to design randomised sequence trials.
Shares Registry-embedded randomisation of treatment order in routine care, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares ADC sequencing, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Registry-embedded randomisation of treatment order in routine care, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, ADC sequencing, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.